This content is restricted.
Brief
On 12/02/2025, the Medicines and Healthcare products Regulatory Agency (MHRA) issued an update regarding Medical imaging agent gozetotide approved for prostate cancer. The MHRA has approved gozetotide, brand name Illuccix, to be used in PET scans for detecting specific types of cancer cells in adults with prostate cancer.
Highlights content goes here...
This content is restricted.

RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested